Tel: 0845 251 1000
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander
  • COMBAT Alexander

Medical Batteries


Combat Alexander has been supplying medical batteries and medical battery packs for over 25 years. As a leader in our field, we have an excellent reputation within the medical sector for our product quality and customer service.


Combat Alexander has been providing an excellent service to the Medical Sector for over 25 years.  Supplying high quality medical betteries and medical battery packs to the industry with great pride.

We work with lots of departments within the NHS supplying them with the quality products thay they need. We stock a comprehensive range of original batteries or replacement batteries.   If you do not see what you need on our website please feel free to give us a call.
 

NIMH Batteries
Medical Batteries
Panasonic Batteries
Hearing Aid Batteries
YUASA
S.L.A. (Sealed Lead Acid)
Sonnenschein Medical
Lithium Batteries
Nicad Batteries
Alkaline Batteries
Duracell Batteries
Physio Batteries
Odyssey Batteries
Trojan Batteries
Sonnenschein UPS
Refurbishments

 




Warning: Creating default object from empty value in /home/sites/5a/9/9ee92dd20f/public_html/main/modules/mod_feed/helper.php on line 46
MDDI
Medical Device and Diagnostics Industry
  • Misinterpretation of Jaundice Meters Triggers a Recall

    Draeger Medical Systems is recalling its Jaundice Meter JM-103 and JM-105 models after some users have misinterpreted display messages that have resulted in serious injuries, according to an FDA notice.

    The Jaundice Meters are used to measure bilirubin in newborns. Specifically, the JM-103 model displays three blinking dashes (---) and the JM-105 meter displays dash-zero-dash (-0-) when the bilirubin level in the patient is higher than the maximum level of detection. Measurement of high bilirubin indicates a need for immediate medical evaluation. Some users have interpreted the two display messages as indicating a low or zero value instead of high bilirubin levels. When this happens, FDA said, treatment may be delayed or not offered, which could lead to brain damage and possibly death in some babies.

    The out of range display is visible; however, the interpretation of the reading is not intuitive or clear, FDA said.

    The recall includes 2,449 JM-103 models manufactured between June 2008 and August 2017 and distributed between July 2008 and September 2017; and 2,063 JM-105 models manufactured between September 2013 and April 2018 and distributed between October 2013 and April 2018.

    FDA noted that the Jaundice Meters are intended for use in hospitals or doctors' offices under a physician's supervision or at their direction to assist clinicians in monitoring newborn infants. The device is not intended as a standalone screening device for diagnosis of hyperbilirubinemia, the agency said. It is used as a screening device along with other clinical assessments and laboratory measurements.

    The JM-105 meter is a modification of the JM-103 meter. The basic functionality, including the measuring probe, hardware, and software used to process the measurements are identical to the earlier model. The display of the later model includes a larger screen and touchscreen, and data storage and transmission functionality. 

  • Medtronic and IBM Launch a Sweet New Diabetes App

    Artificial intelligence continues to prove valuable across many healthcare specialties, but diabetes management really seems to stand out as an area where AI can truly make a direct impact on patient lives.

    The latest example of the industry embracing AI's capabilities for the millions of people living with diabetes is an app co-developed by Medtronic and IBM Watson Health dubbed the Sugar.IQ smart diabetes assistant. The app is designed to simplify and improve daily diabetes management by leveraging AI and analytic technologies from IBM Watson Health to continually analyze how an individual's glucose level responds to their food intake, insulin dosages, daily routines, and other factors.

    The idea is that the app will help people with diabetes uncover patterns that affect their glucose levels, which can help them make small adjustments throughout the day to stay on track.

    According to data presented at the American Diabetes Association Scientific Sessions on Friday, people who used the Sugar.IQ app spent 36 minutes more per day in healthy glucose range than they did before using the app. This included 30 minutes less time in hyperglycemia (>180 mg/dL) and six minutes less time in hypoglycemia (<70 mg/dL). This represents more than nine additional days in a year that a person with diabetes is spending in a healthy glucose range.

    Michelle Shaw, a Medtronic employee and registered nurse, has been using the Sugar.IQ app for four weeks through an employee preview program.

    “Sugar.IQ has given me insights that I could never have uncovered on my own, even with 30 years of diabetes experience," Shaw said. "It’s been eye-opening and fun to gain new insights into my diabetes without additional burden.”

    The app is available to people who use the Medtronic Guardian Connect system, a standalone continuous glucose monitoring system. It is currently available for iOS-based mobile devices in the United States.

    Recently Medtronic also updated its iPro2 myLog app with FoodPrint report. The iPro2 myLog app is designed to give clinics a simple way to import patients' logged data during their professional iPro2 continuous glucose monitoring (CGM) evaluation. With the addition of Nutrino's FoodPrint report, patients' meals are graded based on their body's unique glucose reaction, making it easy for them to understand the link between meals and glucose variability, the company said.

     

  • Is Eversense the Latest Game Changer in the Diabetes Market?

    Senseonics’ newly approved Eversense implantable continuous glucose monitoring (CGM) system could be in patient’s hands as early as next month. Tim Goodnow, the Germantown, MD-based company’s president and CEO spoke with MD+DI just a few hours removed from the start of the American Diabetes Association’s 78th Scientific Sessions in Orlando, FL. about the approval and upcoming plans for the device.

    “We think we’ll have our first patients on the product in the third week of July, so it will take us just about a month,” Goodnow, told MD+DI. “We’ve got to print some of the instruction manuals that were approved by FDA now that we have the final wording.”

    The Eversense CGM system uses a small sensor that is implanted just under the skin by a qualified health care provider during an outpatient procedure. After it is implanted, the sensor regularly measures glucose levels in adults with diabetes for up to 90 days.

    Goodnow said there are plans in development for a sensor that can last up to 180 days and another that can last for up to a year.

    Although Eversense has just received FDA approval it has been on the market in Europe for about 21 months.

    “We think Eversense is going to be a very big deal to people,” Goodnow said. “Once a person is diagnosed with diabetes, it’s not curable, but you can manage it effectively and really minimize the long-term effect if you’re very aggressive in managing your glucose control. Diabetes patients already know this, they just want tools and techniques to help them do it easier. They don’t want one more thing to think about. The value of a long-term implantable is it takes the interaction with the sensor off the table.”

    Eversense differs from other technologies developed by some of the larger medtech players in the space.

    “Dexcom, Medtronic, and Abbott all have different twists on their features and attributes, but they all work with what is called a transcutaneous sensor,” Goodnow said. “That means that the sensor goes through the skin and there’s always a small wound or a small opening with any of those technologies.”

    He noted that as a result you have that area protected so you don’t lose the sensor, or have it move around.

    Market Disruptors

    Eversense’s approval is yet another significant development in making diabetes management as less cumbersome as possible. The device is one of several products containing the potential to shake up the diabetes market. MD+DI documented a list of several key events that helped disrupt and reshape the diabetes market.

    Medtronic kicked off the shift in 2016 when it won a nod for its 670 G fully automated closed loop system, dubbed the artificial pancreas.

    Abbott Laboratories would follow nearly a year later with FDA approval of its Freestyle Libre Flash Glucose Monitoring System. Abbott’s Libre is significant because it is being touted as a replacement for blood glucose monitoring. Recently San Diego-based Dexcom’s G6 CGM was classified by FDA as a less-stringent class 11 medical device that is interoperable with other technologies.

  • Supplier Stories for the Week of June 17
  • Senseonics Wins Nod for Implantable Long-Term CGM

    Senseonics Holdings said it has received a PMA for the Eversense Continous Glucose Monitoring (CGM) system. The Germantown, Md-based company said the system is the first and only CGM to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months.

    “We’re very pleased to receive this FDA approval that allows us to make Eversense available in the U.S., as it is in many European markets,” Tim Goodnow President and CEO of Senseonics said in a release. “With the parallel trends of wearable personal devices and medical implantables for people to manage their health, this product exemplifies the natural evolution for diabetes devices, and Senseonics is excited to help lead the way. More importantly, we believe the unique features Eversense offers will help open up CGM to millions of people with diabetes who, up to this point, have been hesitant to try CGM despite the clear health benefits it provides.”

    The Eversense System addresses many of the barriers to CGM use. The system consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. The sensor, which is inserted subcutaneously in the upper arm by a physician via a brief in-office procedure, lasts up to three months, thereby eliminating the need for patients to self-administer the weekly or biweekly sensor insertions required by traditional CGM systems.

    The Eversense CGM System’s PMA application was based on the previously-reported results of the PRECISE II U.S. pivotal trial in which Eversense was studied in 90 adults with type 1 or type 2 diabetes at eight clinical centers in the United States. The study clearly demonstrated the system’s safety and effectiveness over 90 days of continuous glucose sensor wear.

    In March, FDA’s Clinical Chemistry and Clinical Toxicology Devices Panel of independent medical experts voted unanimously, 8 to 0, that the system not only was safe and effective, but also that its benefits outweighed the risks.

    Senseonics has been on the go lately. Earlier this month, the firm began a collaborating with Beta Bionics. The partnership calls for Boston, MA-based Beta Bionics to integrate Senseonics’ Eversense CGM with the iLet Bionic Pancreas System.

    The approval could impact Dexcom, which has taken several hits lately in the CGM market. The San Diego-based received a tremendous blow when when Abbott Laboratories received FDA approval for its FreeStyle Libre Flash, a glucose monitoring system that can be used as replacement for blood monitoring.

     

  • JenaValve Keeps Steady Pace in the TAVR Market

    JenaValve Technology is making steady progress in the development of its next-generation transcatheter aortic valve replacement (TAVR) system. The Irvine, CA-based company said it has implanted the initial patients in a CE mark study for the treatment of severe aortic regurgitation (AR).

    The CE mark study is an international, prospective, non-randomized, single-arm trial of the JenaValve Pericardial TAVR System for the treatment of AR in patients who are at increased risk for conventional surgical valve replacement.

    “Our goal is to enable the treatment of patients with severe aortic regurgitation while avoiding many of the side-effects with off-label use of other TAVR devices in this patient population,” said Victoria Carr-Brendel, PhD, CEO of JenaValve, in a release. “We are excited to initiate this trial and look forward to expanding enrollment across multiple sites, building on this positive initial experience with our partners at the Heart Center of the University of Cologne.”

    The JenaValve system is proprietary and differentiated from currently available TAVR devices due to the Everdur locator-based technology, designed for more predictable implantation using the new 18-Fr equivalent Coronatix Transfemoral Delivery Catheter. The optimized TAVR system has now been used to treat several AR patients in Germany.

    JenaValve said it could have CE mark approval for treating patients with severe aortic regurgitation by the second half of 2019. The company completed patient enrollment in a CE Mark study of the JenaValve Pericardial TAVR System for the percutaneous treatment of severe aortic stenosis and expects approval before the end of 2018.

    Positive and consistent moves will help JenaValve flourish in the TAVR market, which is already heavily dominated by Edwards Lifesciences and Medtronic in the U.S. Both of the companies popped up several times when MD+DI published six heart-pumping changes in the TAVR market.

    Irvine, CA-based Edwards is the noted pioneer of TAVR having received FDA approval for the Sapien Valve in 2011. Dublin-based Medtronic gained approval for its CoreValve system in 2015. Medtronic gained access to the technology when it acquired CoreValve for more than $700 million in 2009.

     

  • Zimmer Biomet Cancels BoneSupport Orders

    Swedish orthobiologics company BoneSupport has decided to cut out the middleman and set up its own U.S. distribution network to sell its Cerament bone void filler in the United States.

    The Lund, Sweden-based company currently has an exclusive distribution agreement with Zimmer Biomet that is supposed to be in place until Oct. 20, but now that BoneSupport has decided to take control of its commercial platform in the United States, Zimmer Biomet has canceled the major of its orders for a three-month period starting in June.

    BoneSupport CEO Emil Billbäck said the company's evaluation of potential distribution partners is "progressing to plan" and that the company expects to have a strong coverage in the U.S. market in place in late October that will position BoneSupport to create a more direct and stronger relationship with its U.S. customer base.

    "This enhanced commercial platform will allow us to successfully market our highly differentiated products, particularly Cerament G, which we aim to launch in the U.S. market in 2021," Billbäck said.

    Zimmer Biomet retains the right to sell and distribute Cerament bone void filler on an exclusive basis until Oct. 20, and on a non-exclusive basis until April 20, 2019, BoneSupport noted.

    For Zimmer Biomet, the news comes as the company is in the throes of a reboot under new CEO Bryan Hanson, who joined the company last December.

  • Bridging the Healthcare Interoperability Gap

    Interoperability has been a major challenge in healthcare since the early days of electronic medical records. A 2015 survey of nurses found that the lack of interoperability between medical devices and electronic health records is not only burdensome for them but can lead to dangerous medical errors.

    Some healthcare organizations have attempted to integrate their systems to streamline data, but doing so has been a slow, expensive process that is also difficult to maintain. Now, a startup company founded just last year, has developed an integration platform as a service intended to ease some of that pain for healthcare organizations.

    Palm Beach Gardens, FL-based Bridge Connector recently raised $4.5 million in seed funding from Tampa, FL-based Axioma Ventures. Bridge Connector allows healthcare organizations to connect disparate systems like electronic medical record systems, billing systems, lab systems, etc.

    "We've come up with a system that can really help them automate their data flows," CEO David Wenger told MD+DI

    Bridge Connector acts as a secure pipeline between end-points, moving medical data between systems directly, without needing to store sensitive electronic healthcare information in another database. Data is transferred through a local session using AES 256-bit encryption, and all data is cleared once the transfer is complete, the company noted.

    The seed funding is backed by Howard Jenkins, former CEO of Publix Super Markets, who joined Bridge Connector earlier this year as chief strategy officer. Wenger said he feels fortunate to work with Jenkins on a daily basis and learning from his leadership expertise.

    "He's really mentored me on how to build a company as fast as we're trying to build a company," Wenger said.

    In January the company had six employees, today it has 25, and Wenger said he expects the company to grow rapidly and have roughly 45 employees by the end of the year. That growth is what the seed funds will support, he said, but it has been driven largely by the demand for the product.

    “Bridge Connector offers an inexpensive solution to an expensive problem, enabling healthcare organizations to streamline their data flows so they can focus on the treatment of their patients, rather than their data management," Wenger said.

    He explained that one of the advantages of using a subscription-based model is that when Bridge Connector gets a new client that needs to integrate a system the company has already worked with, "we're 85% of the way there." At that point, he said, it's just a matter of customization and field mapping, and the company can deploy the integration for that customer very quickly.

    Bridge Connector is targeting a multi-billion market opportunity that shows no signs of slowing down.

    "There are so many devices and apps and different types of technology that really smart people are creating, but at the end of the day there's still no way to connect it to the other systems that exist already ... so to enable true interoperability in healthcare there needs to be companies like Bridge Connector that can connect any two systems or any three systems or any five systems, regardless of what they're built on," Wenger said.

  • MedAware Uses AI to Tackle Medical Errors and Opioid Epidemic

    Artificial intelligence has been used in a wide variety of devices and services in healthcare. MedAware is using AI and machine learning to help tackle medication errors and abuse of opioids. The Raanana, Israel-based company will collaborate with Allscripts Healthcare Solutions to tackle the problem.

    “A systematic problem calls for a systemic solution,” Gidi Stein, MedAware’s co-founder and CEO, told MD+DI. “We came in trying to tackle this problem using machine learning and AI on large scale electronic medical records.”

    Under this collaboration, Allscripts will implement MedAware’s machine learning-enabled decision support and patient safety solutions to the dbMotion, a healthcare information exchange platform, to provide better patient care.

    In order to provide actionable insights at the point of care and after the script was already filled, MedAware monitors patients’ clinical records to detect medication-related risks, evolving adverse drug events (ADEs), and to identify patient-specific risk of opioid dependency. As a result, in live clinical settings, providers mostly choose to revise their prescriptions when they are notified of such risks from MedAware.

    MedAware said this level of success is achieved by using its medication monitoring technology that leverages machine-learning algorithms and outlier detection mechanisms to identify adverse drug events and flag potentially life-threatening prescriptions that are in conflict with the profile of the patient, physician, or institution.

    The company was formed in 2012 and raised about $8 million in a series A round.

    “We’re now in the midst of our series B [round], and the goal of this round is to accelerate the sales and marketing in the U.S.,” Stein said. “Since the founding of the company and development of the core technology and proof of concept in leading institutions … we’re able to pursue the U.S. market.”

    MedAware’s business model would not have been quite as effective 10 years ago, Stein said.

    “Today, there are several factors to make such a business grow, as opposed to 10 years ago,” he said. “Ten years ago, patient medical record usage was about 10% to 20% in healthcare intuitions in the U.S. … now it’s over 90%. “I think the understanding and the entrance of interoperability followed by meaningful [are key factors].”

    He added, there is also more of a focus on stopping medical errors than it was a decade ago.

  • Medtronic’s Momentum in Innovation Continues

    Medtronic seems to be on a roll when it comes to innovation. The Dublin-based company has received the greenlight from FDA for an expanded indication of the Kyphon HV-R Bone Cement.

    Under the new indication, Medtronic can market Kyphon for the fixation of pathological fractures of the sacral vertebral body using sacral vertebroplasty or sacroplasty.

    Sacral insufficiency fractures (SIFs) are a common cause of debilitating back pain. SIFs mimic the symptoms of lumbar spine pathology. Studies show more than two-thirds of patients diagnosed with SIFs aren't able to associate their pain with a traumatic event. As a result, physicians often prescribe conservative treatment, including physical therapy and prolonged bed rest.

    "Early intervention is an important consideration for both hospital costs and patient outcomes," said Jeff Cambra, vice president and general manager of the Interventional Pain Therapies business, which is part of the Restorative Therapies Group at Medtronic said in a release. "Combined with our 20 years of experience in vertebral compression fractures, this new indication for our bone cement solution allows us to continue to make an impact on vertebral compression fracture and sacral insufficiency diagnosis treatment in the U.S. by giving physicians options to deliver the best clinical solutions to their patients."

    Medtronic gained access to the technology when it acquired Kyphon for $3.9 billion in 2007.

    This is the second technology Medtronic has brought to the forefront in as many days. The firm said it had a partnership with Tel Aviv, Israel-based Nutrion to use the Foot Print Report along with the myLog app to help make it easier for patients to understand the link between meals and glucose variability.